Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

It encompasses a spectrum of diseases ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH) and can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. The global ...

Non-Alcoholic Fatty Liver Disease (NAFLD) is emerging as a significant global health concern, driven by increasing rates of obesity, diabetes and sedentary lifestyles. NAFLD includes a spectrum of ...

A new study has revealed that About 84 per cent of the IT employees in India are suffering from Metabolic Dysfunction-Associated Fatty Liver Disease ... includes a wide spectrum of liver injury ...

Identify the warning signs of hepatitis before they become serious. From subtle fatigue to more obvious symptoms, recognizing liver inflammation early can save.

None other than non-alcoholic steatohepatitis (NASH), the fatty liver disease that is in the ... underpinnings of the biology and clinical spectrum of NASH.” ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

(NALD)(Shutterstock) According to him, NAFLD, if severe and progressing, can lead to an irreversible condition—liver cirrhosis, with non-alcoholic steatohepatitis (NASH) and liver fibrosis as ...

but untreated disease can progress to severe conditions such as non-alcoholic steatohepatitis (NASH), cirrhosis, or liver cancer.” Although no specific drugs are approved yet for treating NAFLD ...